# Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

> **NCT02400281** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arog Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Crenolanib besylate
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Azacytidine
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide
- **DRUG:** Fludarabine
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT02400281
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02400281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02400281, "Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02400281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*